Used in the treatment of metastatic colorectal cancer and advanced gastrointestinal stromal tumors, particularly in patients who have already undergone prior therapy. It functions as a multikinase inhibitor, targeting key pathways involved in tumor angiogenesis, oncogenesis, and the tumor microenvironment. By inhibiting these pathways, it helps slow down cancer progression and prolong survival in certain patients. Also approved for use in hepatocellular carcinoma after failure of prior systemic therapy. Administered orally in tablet form, it is part of a systemic treatment regimen for advanced cancers where surgical options are limited.